Bill

Bill > S4054


NJ S4054

NJ S4054
Clarifies that testosterone therapy is covered treatment under the "New Jersey Menopause Coverage Act."


summary

Introduced
03/23/2026
In Committee
03/23/2026
Crossed Over
Passed
Dead

Introduced Session

2026-2027 Regular Session

Bill Summary

This bill clarifies that testosterone therapy is a covered treatment under the "New Jersey Menopause Coverage Act." Under the bill, health insurance carriers (including insurance companies, hospital service corporations, medical service corporations, health service corporations, and health maintenance organizations authorized to issue health benefits plans in New Jersey, entities contracted to administer health benefits in connection with the State Health Benefits Program and School Employees' Health Benefits Program, and the New Jersey FamilyCare Program) will be required to cover, as part of their coverage of medically necessary perimenopause and menopause treatments under the "New Jersey Menopause Coverage Act," testosterone therapy. The bill also requires that benefits for the prescribed testosterone therapy be provided to the same extent as for any other hormonal treatment under the bill, and stipulates that prescribed testosterone therapy will not be denied by a carrier if the therapy is not indicated by the federal Food and Drug Administration to be approved for perimenopause or menopause.

AI Summary

This bill clarifies that testosterone therapy is a covered treatment under the "New Jersey Menopause Coverage Act" for various health insurance providers, including insurance companies, hospital service corporations, medical service corporations, health service corporations, and health maintenance organizations (HMOs), as well as state health benefit programs and the New Jersey FamilyCare Program. This means that health insurance carriers must cover medically necessary testosterone therapy for perimenopause and menopause symptoms to the same extent as other hormonal treatments. Importantly, carriers cannot deny coverage for prescribed testosterone therapy even if it's not specifically approved by the federal Food and Drug Administration (FDA) for perimenopause or menopause. The bill also mandates that these entities provide clear information about covered menopause treatments to their members.

Committee Categories

Business and Industry

Sponsors (1)

Last Action

Introduced in the Senate, Referred to Senate Commerce Committee (on 03/23/2026)

bill text


bill summary

Loading...

bill summary

Loading...

bill summary

Loading...